Job cuts limit cardiovascular and diabetes research and development
25 June 2019 | By European Pharmaceutical Review
Pharmaceutical company, Sanofi, will eliminate jobs in France and Germany and end new in-house cardiology research programmes.
List view / Grid view
Cardiovascular disease
Benzodiazepines could decrease mortality in congestive heart failure
25 January 2019 | By European Pharmaceutical Review
Researchers have suggested that benzodiazepines should be the first course of treatment for those with cardiovascular disease and anxiety...
Frequent aspirin use linked to increased bleeding
23 January 2019 | By Iqra Farooq (European Pharmaceutical Review)
A study has found that long term aspirin use increases patients' risk of major bleeding events by 43 percent, with 1 in 200 having a major bleed...
Increasing dose of statins could save more lives
7 December 2018 | By European Pharmaceutical Review
A study has shown that thousands of heart attacks and deaths caused by cardiovascular disease could be prevented through the use of statins...
3D bioprinting technique for artificial organ tissue and arteries
22 October 2018 | By Iqra Farooq (European Pharmaceutical Review)
A 3D bioprinting technique could, in the future, allow the creation of human tissue structures for the analysis of various diseases...
Manufacturing small batches of biopharmaceuticals on demand
1 October 2018 | By Iqra Farooq (European Pharmaceutical Review)
Portable biopharmaceutical drug manufacturers could be the future method of producing the drugs on demand for outbreaks of disease...
Statins study questions their widespread use in the healthy elderly
11 September 2018 | By Mike Stones
A new observational study has identified no benefit from prescribing statins to healthy pensioners aged over 75 to prevent heart disease...
Cardiac monitoring for high-risk breast cancer patients ‘should be prioritised’
8 August 2018 | By Mike Stones
Cardiac monitoring of high-risk breast cancer patients should be prioritised, after research revealed low rates of heart monitoring seen in the patients receiving trastuzumab.
Heart health calculator predicts CVD risk
23 July 2018 | By European Pharmaceutical Review
A new online heart health calculator can predict the age of hearts and the risk to individuals of a serious cardiovascular event or death...
Canakinumab reduces gout rate by more than half
14 June 2018 | By European Pharmaceutical Review
The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half, compared to placebo, regardless of baseline serum urate level.
Nutrition, the microbiome, and Autism Spectrum Disorder: A review
26 June 2017 | By University of Illinois College of Agricultural Consumer and Environmental Sciences (ACES)
Over the last decade, research has revealed more about the human gut microbiome—the environment within the gastrointestinal tract—where microbes, especially bacteria, reside.
Novartis invests in Ionis’ therapies to reduce cardiovascular risk
10 January 2017 | By Niamh Marriott, Digital Editor
Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals and its affiliate Akcea Therapeutics to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII.
FDA to review 3 new diabetes drugs that reduce cardiovascular death risk
5 January 2017 | By Niamh Marriott, Digital Editor
In the trial, empagliflozin significantly reduced the relative risk of the combined primary endpoint of cardiovascular death, non-fatal heart attack by 14%...
Novo Nordisk’s semaglutide reduced major cardiovascular events in 1 in 4 type 2 diabetic adults
21 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Fewer serious adverse events were seen with semaglutide vs placebo; however, treatment discontinuation due to adverse events was more frequent...
New data adds to understanding of Repatha® (evolocumab) in multiple patient populations
23 August 2016 | By Amgen
Amgen will present data evaluating Repatha® (evolocumab) at the upcoming European Society of Cardiology (ESC) Congress 2016 in Rome...
Follow: